BiotechTube

KPS-0373 + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spinocerebellar Degeneration

Conditions

Spinocerebellar Degeneration

Trial Timeline

Nov 15, 2016 → Mar 1, 2018

NCT ID
NCT02889302

About KPS-0373 + Placebo

KPS-0373 + Placebo is a phase 3 stage product being developed by Kissei Pharmaceutical for Spinocerebellar Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT02889302. Target conditions include Spinocerebellar Degeneration.

What happened to similar drugs?

0 of 6 similar drugs in Spinocerebellar Degeneration were approved

Approved (0) Terminated (0) Active (6)
🔄KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
🔄KPS-0373, High dose + KPS-0373, Low dose + PlaceboKissei PharmaceuticalPhase 3
🔄KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
🔄KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
🔄KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
🔄troriluzole + PlaceboBiohavenPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01004016Phase 2Completed
NCT07040137Phase 3Recruiting
NCT02889302Phase 3Completed

Competing Products

15 competing products in Spinocerebellar Degeneration

See all competitors
ProductCompanyStageHype Score
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
40
KPS-0373, High dose + KPS-0373, Low dose + PlaceboKissei PharmaceuticalPhase 3
40
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
40
KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
47
KPS-0373 + PlaceboKissei PharmaceuticalPhase 2
35
KPS-0373Kissei PharmaceuticalPhase 2
35
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
40
varenicline + placeboPfizerPhase 2
35
BIIB132 + BIIB132-Matching PlaceboBiogenPhase 1
18
IVIGBaxterPhase 2
32
Intravenous Immune Globulin (IVIG)BaxterPhase 1
22
ARO-ATXN2 Injection + PlaceboArrowhead PharmaceuticalsPhase 1
33
Troriluzole + Placebo + TroriluzoleBiohavenPhase 2/3
32
BHV-4157BiohavenPre-clinical
24
troriluzole + PlaceboBiohavenPhase 3
38